Pyruvate-Enhanced Cardioprotection during Surgery with Cardiopulmonary Bypass

Albert Yurvati, James L. Blair, Mirza Baig, Robert T. Mallet

Research output: Contribution to journalArticle

35 Citations (Scopus)

Abstract

Objectives: To determine whether pyruvate-fortified cardioplegia solution provides cardioprotection superior to lactate-based cardioplegia solutions in patients undergoing elective coronary revascularization, with specific attention to post-surgical recovery of left ventricular performance as well as biochemical markers of ischemic injury. Design: Prospective, randomized, semi-blinded human trial. Setting: Community-based academic medical center. Participants: Thirty adult patients undergoing elective coronary artery bypass graft surgery. Interventions: Patients were randomized to two 4:1 blood cardioplegia solutions, one pyruvate enhanced and the other lactate based. Hemodynamic and laboratory variables were measured in all patients at pre-cross-clamp, post-cross-clamp, and 4, 6, 8, and 12 hours after bypass. Measurements and Main Results: Relative to lactate-based cardioplegia, pyruvate-fortified cardioplegia sharply increased left ventricular stroke work at 4 to 12 hours after bypass (p < 0.001), lowered coronary sinus troponin I and creatine phosphokinase-MB activities 67% (p < 0.001) and 53% (p < 0.01), respectively, and increased coronary sinus hemoglobin 02 saturation 18% (p < 0.001). Ten patients treated with lactate cardioplegia required β-adrenergic inotropic support postbypass, but only 4 pyruvate-treated patients required β-adrenergic support (p = 0.067). Pyruvate cardioplegia shortened postsurgery hospitalization from 6.3 ± 0.3 to 5.2 ± 0.1 days (p < 0.002). Conclusions: Pyruvate-fortified cardioplegia mitigated myocardial injury during coronary artery bypass surgery and facilitated postsurgical recovery of cardiac performance. Thus, pyruvate-enhanced cardioplegia may provide cardioprotection superior to lactate-based solutions during surgical cardiac arrest.

Original languageEnglish
Pages (from-to)715-720
Number of pages6
JournalJournal of Cardiothoracic and Vascular Anesthesia
Volume17
Issue number6
DOIs
StatePublished - 1 Jan 2003

Fingerprint

Induced Heart Arrest
Cardiopulmonary Bypass
Pyruvic Acid
Lactic Acid
Coronary Sinus
Coronary Artery Bypass
Adrenergic Agents
Troponin I
Wounds and Injuries
Creatine Kinase
Heart Arrest
Hemoglobins
Hospitalization
Biomarkers
Hemodynamics
Stroke
Transplants

Keywords

  • Antioxidant
  • Cardiac troponin I
  • Cardioprotection
  • Coronary revascularization
  • Creatine phosphokinase MB isoform
  • Lactate
  • Pyruvate

Cite this

@article{906b7ab0b91c4291ac8534af83eb156e,
title = "Pyruvate-Enhanced Cardioprotection during Surgery with Cardiopulmonary Bypass",
abstract = "Objectives: To determine whether pyruvate-fortified cardioplegia solution provides cardioprotection superior to lactate-based cardioplegia solutions in patients undergoing elective coronary revascularization, with specific attention to post-surgical recovery of left ventricular performance as well as biochemical markers of ischemic injury. Design: Prospective, randomized, semi-blinded human trial. Setting: Community-based academic medical center. Participants: Thirty adult patients undergoing elective coronary artery bypass graft surgery. Interventions: Patients were randomized to two 4:1 blood cardioplegia solutions, one pyruvate enhanced and the other lactate based. Hemodynamic and laboratory variables were measured in all patients at pre-cross-clamp, post-cross-clamp, and 4, 6, 8, and 12 hours after bypass. Measurements and Main Results: Relative to lactate-based cardioplegia, pyruvate-fortified cardioplegia sharply increased left ventricular stroke work at 4 to 12 hours after bypass (p < 0.001), lowered coronary sinus troponin I and creatine phosphokinase-MB activities 67{\%} (p < 0.001) and 53{\%} (p < 0.01), respectively, and increased coronary sinus hemoglobin 02 saturation 18{\%} (p < 0.001). Ten patients treated with lactate cardioplegia required β-adrenergic inotropic support postbypass, but only 4 pyruvate-treated patients required β-adrenergic support (p = 0.067). Pyruvate cardioplegia shortened postsurgery hospitalization from 6.3 ± 0.3 to 5.2 ± 0.1 days (p < 0.002). Conclusions: Pyruvate-fortified cardioplegia mitigated myocardial injury during coronary artery bypass surgery and facilitated postsurgical recovery of cardiac performance. Thus, pyruvate-enhanced cardioplegia may provide cardioprotection superior to lactate-based solutions during surgical cardiac arrest.",
keywords = "Antioxidant, Cardiac troponin I, Cardioprotection, Coronary revascularization, Creatine phosphokinase MB isoform, Lactate, Pyruvate",
author = "Albert Yurvati and Blair, {James L.} and Mirza Baig and Mallet, {Robert T.}",
year = "2003",
month = "1",
day = "1",
doi = "10.1053/j.jvca.2003.09.007",
language = "English",
volume = "17",
pages = "715--720",
journal = "Journal of Cardiothoracic and Vascular Anesthesia",
issn = "1053-0770",
publisher = "W.B. Saunders Ltd",
number = "6",

}

Pyruvate-Enhanced Cardioprotection during Surgery with Cardiopulmonary Bypass. / Yurvati, Albert; Blair, James L.; Baig, Mirza; Mallet, Robert T.

In: Journal of Cardiothoracic and Vascular Anesthesia, Vol. 17, No. 6, 01.01.2003, p. 715-720.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Pyruvate-Enhanced Cardioprotection during Surgery with Cardiopulmonary Bypass

AU - Yurvati, Albert

AU - Blair, James L.

AU - Baig, Mirza

AU - Mallet, Robert T.

PY - 2003/1/1

Y1 - 2003/1/1

N2 - Objectives: To determine whether pyruvate-fortified cardioplegia solution provides cardioprotection superior to lactate-based cardioplegia solutions in patients undergoing elective coronary revascularization, with specific attention to post-surgical recovery of left ventricular performance as well as biochemical markers of ischemic injury. Design: Prospective, randomized, semi-blinded human trial. Setting: Community-based academic medical center. Participants: Thirty adult patients undergoing elective coronary artery bypass graft surgery. Interventions: Patients were randomized to two 4:1 blood cardioplegia solutions, one pyruvate enhanced and the other lactate based. Hemodynamic and laboratory variables were measured in all patients at pre-cross-clamp, post-cross-clamp, and 4, 6, 8, and 12 hours after bypass. Measurements and Main Results: Relative to lactate-based cardioplegia, pyruvate-fortified cardioplegia sharply increased left ventricular stroke work at 4 to 12 hours after bypass (p < 0.001), lowered coronary sinus troponin I and creatine phosphokinase-MB activities 67% (p < 0.001) and 53% (p < 0.01), respectively, and increased coronary sinus hemoglobin 02 saturation 18% (p < 0.001). Ten patients treated with lactate cardioplegia required β-adrenergic inotropic support postbypass, but only 4 pyruvate-treated patients required β-adrenergic support (p = 0.067). Pyruvate cardioplegia shortened postsurgery hospitalization from 6.3 ± 0.3 to 5.2 ± 0.1 days (p < 0.002). Conclusions: Pyruvate-fortified cardioplegia mitigated myocardial injury during coronary artery bypass surgery and facilitated postsurgical recovery of cardiac performance. Thus, pyruvate-enhanced cardioplegia may provide cardioprotection superior to lactate-based solutions during surgical cardiac arrest.

AB - Objectives: To determine whether pyruvate-fortified cardioplegia solution provides cardioprotection superior to lactate-based cardioplegia solutions in patients undergoing elective coronary revascularization, with specific attention to post-surgical recovery of left ventricular performance as well as biochemical markers of ischemic injury. Design: Prospective, randomized, semi-blinded human trial. Setting: Community-based academic medical center. Participants: Thirty adult patients undergoing elective coronary artery bypass graft surgery. Interventions: Patients were randomized to two 4:1 blood cardioplegia solutions, one pyruvate enhanced and the other lactate based. Hemodynamic and laboratory variables were measured in all patients at pre-cross-clamp, post-cross-clamp, and 4, 6, 8, and 12 hours after bypass. Measurements and Main Results: Relative to lactate-based cardioplegia, pyruvate-fortified cardioplegia sharply increased left ventricular stroke work at 4 to 12 hours after bypass (p < 0.001), lowered coronary sinus troponin I and creatine phosphokinase-MB activities 67% (p < 0.001) and 53% (p < 0.01), respectively, and increased coronary sinus hemoglobin 02 saturation 18% (p < 0.001). Ten patients treated with lactate cardioplegia required β-adrenergic inotropic support postbypass, but only 4 pyruvate-treated patients required β-adrenergic support (p = 0.067). Pyruvate cardioplegia shortened postsurgery hospitalization from 6.3 ± 0.3 to 5.2 ± 0.1 days (p < 0.002). Conclusions: Pyruvate-fortified cardioplegia mitigated myocardial injury during coronary artery bypass surgery and facilitated postsurgical recovery of cardiac performance. Thus, pyruvate-enhanced cardioplegia may provide cardioprotection superior to lactate-based solutions during surgical cardiac arrest.

KW - Antioxidant

KW - Cardiac troponin I

KW - Cardioprotection

KW - Coronary revascularization

KW - Creatine phosphokinase MB isoform

KW - Lactate

KW - Pyruvate

UR - http://www.scopus.com/inward/record.url?scp=0346099364&partnerID=8YFLogxK

U2 - 10.1053/j.jvca.2003.09.007

DO - 10.1053/j.jvca.2003.09.007

M3 - Article

C2 - 14689411

AN - SCOPUS:0346099364

VL - 17

SP - 715

EP - 720

JO - Journal of Cardiothoracic and Vascular Anesthesia

JF - Journal of Cardiothoracic and Vascular Anesthesia

SN - 1053-0770

IS - 6

ER -